Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, today announced positive topline results from its Phase 2b clinical study of AR882 for the treatment of chronic gout, providing a strong foundation to advance into Phase 3 clinical development.
Viva Biotech ranked sixth among the Top 20 Chinese R&D CRO Enterprises in 2022. Its subsidiary, Langhua Pharmaceutical, was named among the Top 20 Chinese CDMO Enterprises in 2022.
VivaVision and Everads Therapy announced a partnership to develop treatments for retinal diseases using Everads Therapy’s suprachoroidal delivery technology.
Viva Ventures Biotech Fund invests in early-stage drug discovery startups and has partnered with entrepreneurial scientists.
Viva Ventures Biotech Fund
Viva Ventures Biotech Fund is a large-scale investment firm focusing on biotech startups, supporting companies from the idea stage to inception. The firm typically invests in various stages, including Seed, Series A, and Series C rounds, providing significant financial backing to foster innovation in the biotech sector.
